We are elated to share some exhilarating news from the life sciences industry front! BioSpace, a renowned name in the life sciences news and careers sector, recently unveiled its much-anticipated NextGen Bio "Class of 2023" list. This annual compilation celebrates the top 25 groundbreaking biopharma companies with immense innovation and success potential.
Spanning its ninth year, the list shines a spotlight on new-age companies from all corners of the U.S. that are making remarkable strides in biopharmaceuticals. Topping this list is Neumora Therapeutics, which has commendably amassed significant funding over the last two years and fortified its pipeline with numerous programs.
What sets the NextGen Bio list apart is the meticulous evaluation process BioSpace's editorial team undertakes. Factors such as growth potential, innovation, collaborations, financing, and pipeline depth are scrutinized. Based on these metrics, points are awarded, and organizations are ranked. Companies that made their mark between September 2021 and September 2022 with Series A funding had a prominent place in this year's list.
We at Totus Medicines are immensely proud to find our name alongside industry trailblazers, reflecting our unwavering commitment to developing innovative solutions. Josh Goodwin, the CEO of BioSpace, encapsulated the sentiment perfectly: "With so much momentum in our industry, it's a thrill to highlight key innovators that show particular promise."
The achievements of companies like Eikon Therapeutics, Prime Medicine, Umoja Biopharma, and GentiBio in previous editions of the NextGen list exemplify the credibility and prestige associated with this honor. We are both humbled and excited to be a part of such an esteemed group.
Here's a quick look at the companies making waves in the "NextGen Class of 2023":
- Neumora Therapeutics
- Altos Labs
- Odyssey Therapeutics
- Affini-T Therapeutics
- Upstream Bio
- Totus Medicines (Yes, that's us!)
[Complete list can be found on BioSpace]
A bit about BioSpace: For those unfamiliar with BioSpace, they are the industry torchbearers, offering unparalleled insights, opportunities, and tools. They bridge the gap between groundbreaking life sciences organizations and skilled professionals dedicated to enhancing health and quality of life globally.
We're thrilled to continue our journey in life sciences, strengthened by this recognition, and remain dedicated to our mission. For more updates and breakthroughs from our side, stay tuned to the Totus Medicines blog.
View Press Release